Biblio Discovery — Demo Discovery Service

7 hasil untuk "Scott N. Gettinger"

Menampilkan 1–7 · 0,77 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

    David Robert Spigel; David Vicente; Tudor–Eliade Ciuleanu dkk.

    Annals of Oncology · 2021 · Inggris · OpenAlex Scopus

    BACKGROUND: Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. PATIENTS AND METHODS: CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus standard…

  2. Artikel Jurnal

    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first…

  3. Artikel Jurnal Teks lengkap

    Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim…

  4. Artikel Jurnal Teks lengkap

    Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    Hossein Borghaei; Scott N. Gettinger; Everett E. Vokes dkk.

    Journal of Clinical Oncology · 2021 · Inggris · OpenAlex Scopus

    PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated…

  5. Artikel Jurnal Teks lengkap

    NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    David S. Ettinger; Douglas E. Wood; Dara L. Aisner dkk.

    Journal of the National Comprehensive Cancer Network · 2021 · Inggris · OpenAlex Scopus

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective…

  6. Artikel Jurnal Teks lengkap

    NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

    David S. Ettinger; Douglas E. Wood; Dara L. Aisner dkk.

    Journal of the National Comprehensive Cancer Network · 2023 · Inggris · OpenAlex Scopus

    The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.